Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04699721 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 1, 2020 to Sep 2, 2020 Show 6 more changesShow less
    • Primary completion date changed from estimate of Sep 2027 to Dec 31, 2024
    • Interventions modified
    • Enrollment target: estimated 60 to confirmed 65
    • Study completion date: Dec 2027 to Dec 31, 2027
    • Eligibility criteria shortened, about 6 words
    • Secondary endpoints: 9 to 6
  2. Phase: Phase 1 to Phase 2v3 Show 5 more changesShow less
    • Enrollment target: 40 to 60
    • Primary endpoints: 3 to 1
    • Eligibility criteria expanded, about 46 words
    • Secondary endpoints: 5 to 9
    • Study title revised
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    • Study arms: 0 to 1
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the safety and effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics for resectable NSCLC patients.
Trial Details
NCT Number NCT04699721
Lead Sponsor Xiangya Hospital of Central South University
Conditions
(from sponsor)		 Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA, Non-small Cell Lung Cancer Stage IIIB
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 65 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov